Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 11:41 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 457–480 of 593 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: PRIME Clear all
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of Tdap Vaccine Compared to DTaP Vaccine in Children 4 to 6 Years of Age

NCT00467519
View directory record Official record
Conditions
Tetanus, Diphtheria, Pertussis
Interventions
Tdap (Tetanus Toxoid Reduced Diphtheria Toxoid/Acellular Pertussis), DTaP (Diphtheria & Tetanus Toxoids & Acellular Pertussis Adsorbed)
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
4 Years to 6 Years
Enrollment
1,045 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
42
States / cities
Birmingham, Alabama • Fayetteville, Arkansas • Jonesboro, Arkansas + 34 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2014 · Synced Oct 25, 2026, 11:41 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune Response to a DNA Vaccine and a Recombinant HIV-1-MVA Vaccine, Separately and in Combination, in Healthy Adults

NCT00428337
View directory record Official record
Conditions
HIV Infections
Interventions
EP-1233, MVA-mBN32
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 40 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
3
States / cities
San Francisco, California • Rochester, New York • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 14, 2021 · Synced Oct 25, 2026, 11:41 AM EDT
Completed Not applicable Interventional Results available

Cognitive Priming for Stroke Tele-rehabilitation

NCT06555302
View directory record Official record
Conditions
Stroke
Interventions
Cognitive Rehabilitation, Occupational Therapy
Behavioral
Lead sponsor
Medical University of South Carolina
Other
Eligibility
21 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 25, 2026, 11:41 AM EDT
Withdrawn Phase 2 Interventional

CASCADE: Testing for Safety and Immune Effects of PDS0101, an Anti-HPV Therapy, Among People Living With HIV

NCT07090174
View directory record Official record
Conditions
HPV Associated Cancers, HIV (Human Immunodeficiency Virus), Anal Cancer, Cervical Cancer, HPV 16 Infection
Interventions
PDS0101
Biological
Lead sponsor
University of California, San Diego
Other
Eligibility
25 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
2
States / cities
New York, New York • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 25, 2026, 11:41 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Safety, Tolerability, and Bioavailability of Subcutaneous Lirentelimab (AK002) in Adult Healthy Volunteers

NCT04324268
View directory record Official record
Conditions
Study Conducted in Healthy Volunteers
Interventions
lirentelimab (AK002), Placebo
Drug · Other
Lead sponsor
Allakos Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Edgewater, Florida
Source: ClinicalTrials.gov public record
Updated Apr 18, 2023 · Synced Oct 25, 2026, 11:41 AM EDT
Not listed Not applicable Interventional

Blood Conservation in Patients (3.5-12kg) Undergoing Congenital Cardiac Surgery

NCT05881564
View directory record Official record
Conditions
Congenital Heart Disease
Interventions
blood use for priming cardiopulmonary bypass circuit, clear prime for cardiopulmonary bypass
Other
Lead sponsor
Augusta University
Other
Eligibility
Not listed
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 1, 2023 · Synced Oct 25, 2026, 11:41 AM EDT
Active, not recruiting Not applicable Interventional Results available

ACURATE IDE: Safety and Effectiveness Study of ACURATE Valve for Transcatheter Aortic Valve Replacement

NCT03735667
View directory record Official record
Conditions
Aortic Stenosis
Interventions
ACURATE neo2™ Transfemoral TAVR System, Medtronic CoreValve TAVR System, Edwards SAPIEN 3 TAVR System, ACURATE Prime™ Transfemoral TAVR System XL
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
Not listed
Enrollment
1,948 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
69
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 58 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 25, 2026, 11:41 AM EDT
Completed Phase 1Phase 2 Interventional

A Study of a Personalized Neoantigen Cancer Vaccine

NCT03639714
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Colorectal Cancer, Gastroesophageal Adenocarcinoma, Urothelial Carcinoma
Interventions
GRT-C901, GRT-R902, nivolumab, ipilimumab
Biological
Lead sponsor
Gritstone bio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
10
States / cities
Phoenix, Arizona • Jacksonville, Florida • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2023 · Synced Oct 25, 2026, 11:41 AM EDT
Active, not recruiting Not applicable Interventional

An EFS to Evaluate the CGuard Prime™ Carotid Stent in Acute Ischemic Stroke

NCT06447116
View directory record Official record
Conditions
Acute Ischemic Stroke
Interventions
CGuard Prime™ Carotid Stent System
Device
Lead sponsor
Jacobs institute
Other
Eligibility
18 Years to 90 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Oct 25, 2026, 11:41 AM EDT
Active, not recruiting Not applicable Interventional

Exercise Primed Stroke Rehabilitation

NCT04877444
View directory record Official record
Conditions
Stroke
Interventions
Duck Duck Punch, Aerobic exercise, Lower extremity stretching
Device · Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
50 Years to 90 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 25, 2026, 11:41 AM EDT
Completed Not applicable Interventional Results available

ABSORB III Randomized Controlled Trial (RCT)

NCT01751906
View directory record Official record
Conditions
Coronary Artery Disease, Coronary Artery Stenosis, Coronary Disease, Coronary Stenosis
Interventions
Absorb BVS, XIENCE
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
2,008 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
190
States / cities
Birmingham, Alabama • Fairhope, Alabama • Montgomery, Alabama + 145 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2023 · Synced Oct 25, 2026, 11:41 AM EDT
Completed Phase 2 Interventional Results available

Id-KLH Vaccine + T Cells in Subjects With Myeloma Undergoing Transplant

NCT01426828
View directory record Official record
Conditions
Multiple Myeloma
Interventions
CD3/CD28
Biological
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 4, 2020 · Synced Oct 25, 2026, 11:41 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Increased Frequency of AlloStim(TM) Dosing in Combination With Cryoablation in Metastatic Breast Cancer Patients

NCT02018419
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
AlloStim, Cryoablation
Biological · Procedure
Lead sponsor
Mirror Biologics, Inc.
Industry
Eligibility
18 Years to 70 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jan 22, 2020 · Synced Oct 25, 2026, 11:41 AM EDT
Completed Phase 1 Interventional

Nivolumab/Ipilimumab-Primed Immunotransplant for DLBCL

NCT03305445
View directory record Official record
Conditions
Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
Interventions
Ipilimumab, Nivolumab
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 15, 2023 · Synced Oct 25, 2026, 11:41 AM EDT
Completed Phase 1 Interventional

Pediatric Hemiplegia: Synergistic Treatment Using rTMS and CIT

NCT01104064
View directory record Official record
Conditions
Stroke
Interventions
real rTMS combined with constraint induced therapy, sham rTMS combined with constraint induced therapy
Device
Lead sponsor
University of Minnesota
Other
Eligibility
8 Years to 16 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 19, 2013 · Synced Oct 25, 2026, 11:41 AM EDT
Completed Phase 4 Interventional Results available

GrafixPL PRIME Evaluation Case Study

NCT03742440
View directory record Official record
Conditions
Diabetic Foot Ulcer
Interventions
GrafixPL PRIME
Biological
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 90 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 24, 2023 · Synced Oct 25, 2026, 11:41 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

BCG and Plasma Amyloid in Non-Demented Adults

NCT04449926
View directory record Official record
Conditions
Alzheimer Disease, Late Onset
Interventions
Bacillus of Calmette and Guerin (BCG)
Biological
Lead sponsor
Mindful Diagnostics and Therapeutics, LLC
Industry
Eligibility
50 Years to 80 Years
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Eau Claire, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 23, 2021 · Synced Oct 25, 2026, 11:41 AM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune Response to Polyvalent HIV-1 Vaccine in HIV Uninfected Adults

NCT00061243
View directory record Official record
Conditions
HIV Infections
Interventions
HIV-1 DNA vaccine with protein vaccine boost
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2010
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 26, 2008 · Synced Oct 25, 2026, 11:41 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Mechanisms of Impaired Brain Blood Flow With Aging

NCT03775382
View directory record Official record
Conditions
Aging
Interventions
Ascorbic Acid, Normal Saline
Other
Lead sponsor
University of Delaware
Other
Eligibility
18 Years to 79 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated May 10, 2023 · Synced Oct 25, 2026, 11:41 AM EDT
Recruiting Phase 1Phase 2 Interventional

Enfortumab Vedotin and Pembrolizumab Combined With Radiotherapy in Muscle Invasive Bladder Cancer

NCT06470282
View directory record Official record
Conditions
Bladder Cancer, Muscle-Invasive Bladder Carcinoma, Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8
Interventions
Enfortumab Vedotin, Pembrolizumab, Intensity Modulated Radiation Therapy (IMRT), Transurethral Resection of Bladder Tumor, Cystoscopy (CS), Computed Tomography (CT), Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET)
Drug · Biological · Radiation + 1 more
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 25, 2026, 11:41 AM EDT
Terminated Phase 3 Interventional Results available

Safety & Efficacy Study Evaluating the Combination of Bevasiranib & Lucentis Therapy in Wet AMD

NCT00499590
View directory record Official record
Conditions
Macular Degeneration
Interventions
bevasiranib, ranibizumab
Drug
Lead sponsor
OPKO Health, Inc.
Industry
Eligibility
50 Years and older
Enrollment
338 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
55
States / cities
Phoenix, Arizona • Tucson, Arizona • Fresno, California + 47 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2014 · Synced Oct 25, 2026, 11:41 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Safety, Tolerability, and Immunogenicity of a Prime-Boost Regimen of HIV-1 Nef/Tat/Vif, Env pDNA Vaccine Delivered Intramuscularly With Electroporation and HIV-1 rVSV envC Vaccine in Healthy, HIV-Uninfected Adults

NCT02654080
View directory record Official record
Conditions
HIV Infections
Interventions
HIV-1 nef/tat/vif, env pDNA vaccine, rVSV HIV envC vaccine, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
2
States / cities
Cleveland, Ohio • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 15, 2021 · Synced Oct 25, 2026, 11:41 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Pro2col Application on Health Outcomes

NCT06738641
View directory record Official record
Conditions
Health Behavior, Nutrition, Healthy, Activity, Motor
Interventions
Pro2col Health, Control
Behavioral
Lead sponsor
Applied Science & Performance Institute
Industry
Eligibility
21 Years to 60 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Oct 25, 2026, 11:41 AM EDT
Completed Phase 1 Interventional

Study of SQZ-PBMC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors

NCT04084951
View directory record Official record
Conditions
Adult Solid Tumor
Interventions
SQZ-PBMC-HPV, Atezolizumab, Ipilimumab, Nivolumab
Biological · Drug
Lead sponsor
SQZ Biotechnologies
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
10
States / cities
Scottsdale, Arizona • Los Angeles, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2023 · Synced Oct 25, 2026, 11:41 AM EDT